Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Individual Treatment Effects: Implications for Research, Clinical Practice, and Policy

This research outlines a framework and policy considerations to help health care stakeholders understand when it is important take patients’ individual treatment responses into account when making treatment, coverage and policy decisions.

Increased funding for comparative effectiveness research (CER) has sharpened the interest in learning what works best, for whom, and under what specific clinical circumstances. The goal of CER is to provide patients, payers, clinicians and policymakers with information to assist them in making the best decisions about treatment options. Because not all patients respond in the same way, research findings, treatment decisions, clinical guidelines or coverage policies applied in a “one-size-fits-all” manner based upon the population “average” response may lead to less than ideal health outcomes.

According to the research, four factors were identified that indicate when it may be inappropriate to narrow treatment choices:

  • Consequences of treatment choice are high: There are more significant consequences associated with delaying the optimal treatment choices for some conditions than others. For example, a person suffering from hay fever may try several successive treatments before finding the right one, with no long-term impact, while a person facing acute organ failure may not have the luxury of time or the disease may progress irreversibly while other alternatives are tried.

  • Patient diversity exists: Patients with the same disease often vary in the symptoms they experience. For example, some patients with depression may have sadness, insomnia, or lack of interest in daily activities, whereas others also may have anxiety and agitation.

  • Treatment response is independent of other treatments: The similarity between a patient’s likely responses to the available treatments for a condition (level of “treatment independence”) may vary. Some patients may be very likely to have consistent responses to other treatments, but in other conditions response may vary even when treatments belong to the same or different classes of medicines.

  • Patient preferences vary: Dosing, tolerance of particular side effects, willingness to make necessary behavioral changes and other physical and lifestyle factors all can impact the suitability of a particular treatment regimen for an individual patient.

In addition to understanding when these differences are clinically important, the study also outlines policy recommendations that can help to ensure that the right treatment is delivered to the right patient:

  • Researchers should conduct studies to better understand when, why and how much individual treatment differences matter. When patient response varies, researchers should directly compare treatment alternatives in the same patients. To understand when and why individual patients respond differently, researchers should pre-specify, collect and report individual patient characteristics and patient subgroups in their studies. Additional funding is needed for research to understand the impact of patient preferences on clinical and economic outcomes.

  • Payers should consider flexible coverage and reimbursement policies when individuals differ in their treatment response. When treatment response varies across patients, more flexible and broader coverage and reimbursement is needed. In addition, patients who differ from the population “average” due to their biology or prior response to treatment alternatives should not be required to pay higher out-of-pocket copayments.

  • Providers should ensure that clinical guidelines and patient care incorporate when, how and why individual patient treatment effects matter. Clinical guidelines and quality measures should take individual treatment effects into account.  Funding is needed for research and tools to help providers identify which treatments work best for “similar” patients, and for training to enhance provider-patient communication about an individual patient’s preferences and potential for benefits and risks. Mobile health (mhealth) and other systems can increase the knowledge available to providers and allow them to determine when alternative treatments are needed.
Blog Post

ASCO’s Clinical Pathways Recommendations and Remaining Challenges

The American Society of Clinical Oncology (ASCO) today released its “policy statement on clinical pathways in oncology,” which acknowledges the...
Blog Post

#TBT: “Talk About Your Medicines” Month & A Question Checklist for Patients

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Blog Post

How Can We Assess the Value of a Companion Diagnostic Test?

When President Obama pledged $215 million for a Precision Medicine Initiative during his State of the Union address earlier this year, he...
Blog Post

#TBT: Men’s Health Month & Differences in Prostate Cancer Treatment

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

Washington, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards

Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

The Risks of Standardized Health Care

Think about the last time you visited a medical office. Even at a specialist’s office, chances are that each person waiting for his or her name to be...
Commentary and Testimony Page

When the Sound Bite Doesn’t Tell the Full Story

Not long ago, President Obama was asked at a press conference about comparative effectiveness research (CER) and how it fits into the health care...
YouTube Videos

Using Distributed Data Networks to Understand Heterogeneity in Real-World Data

Kimberly Westrich, director of health services research at the National Pharmaceutical Council, explains how large observational datasets like...
YouTube Videos

Taking Patient Variations Into Account

Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...
YouTube Videos

Payer Views of Individualized Health Care

Dr. Daniel Malone, professor at the University of Arizona School of Pharmacy, explains how payers view the issue of individualized therapy. He says...
YouTube Videos

Dr. Puckrein on the Issue of Individual Patient Differences

Dr. Gary Puckrein, founder and president of the National Minority Quality Forum, says that there is tremendous variability in how different patients...
Blog Post

ASCO’s Clinical Pathways Recommendations and Remaining Challenges

The American Society of Clinical Oncology (ASCO) today released its “policy statement on clinical pathways in oncology,” which acknowledges the...
Blog Post

#TBT: “Talk About Your Medicines” Month & A Question Checklist for Patients

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Blog Post

How Can We Assess the Value of a Companion Diagnostic Test?

When President Obama pledged $215 million for a Precision Medicine Initiative during his State of the Union address earlier this year, he...
Blog Post

#TBT: Men’s Health Month & Differences in Prostate Cancer Treatment

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
  •  
  • 1 of 5
  • >